Abstract Search

ea0070yi6 | Young Investigators | ECE2020

Dysregulation of splicing factor 3B SUBUNIT 1 (SF3B1) is associated with the pathological transformation of the liver: Pharmacological inhibition with pladienolide-B as novel therapeutic tool in liver disease

Jiménez Vacas1 Juan Manuel , López-Cánovas Juan L , Del Rio-Moreno Mercedes , García-Fernandez Helena , Sánchez-Frias Marina E , Amado Victor , L-López Fernando , Fondevila Marcos F , Ciria Ruben , Briceño Javier , Nogueiras Rubén , De la Mata Manuel , Castaño Justo P , Rodriguez-Perálvarez Manuel , Luque Raúl M , Gahete Manuel D

Development and progression of liver diseases, from non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH), and hepatocellular carcinoma (HCC), seem to be accompanied by a dysregulation of the expression of alternative splicing variants (SVs) and appearance of aberrant SVs. The splicing factor 3B subunit 1 (SF3B1) represents a crucial player for the functional assembly of the spliceosome, the core machinery that controls the splicing process, and its activity can ...

0 shares

Endocrine Abstracts

Dysregulation of splicing factor 3B SUBUNIT 1 (SF3B1) is associated with the pathological transformation of the liver: Pharmacological inhibition with pladienolide-B as novel therapeutic tool in liver disease

BiosciAbstracts